1.51 0.00(0.00%) Oct 1, 4:00PM EDT
| Prev Close: | 1.51 |
|---|
| Open: | 1.54 |
|---|
| Bid: | 0.71 x 100 |
|---|
| Ask: | 1.93 x 100 |
|---|
| 1y Target Est: | 2.45 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.50 - 1.55 |
|---|
| 52wk Range: | 1.35 - 3.72 |
|---|
| Volume: | 209,281 |
|---|
| Avg Vol (3m): | 413,902 |
|---|
| Market Cap: | 47.17M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Aeterna Zentaris Completes Successful Transfer of Cetrotide® Manufacturing Rights to Merck KGaAPR Newswire(Tue, Oct 1)
- Aeterna Zentaris Completes Successful Transfer of Cetrotide® Manufacturing Rights to Merck KGaACNW Group(Tue, Oct 1)
- Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New YorkCNW Group(Thu, Aug 29)
- Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New YorkPR Newswire(Thu, Aug 29)
- Aeterna Zentaris Announces Listing Transfer to NASDAQ Capital MarketCNW Group(Wed, Aug 28)
- Aeterna Zentaris Announces Listing Transfer to NASDAQ Capital MarketPR Newswire(Wed, Aug 28)
- Genomics Developments Unlock M&A in Health Care SectorWall Street Transcript(Mon, Aug 26)
- AEterna Zentaris: An Interesting Investment With Long-Term Growth Potentialat Seeking Alpha(Tue, Aug 20)
- Æterna Zentaris Management Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, Aug 9)
- Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating ResultsCNW Group(Thu, Aug 8)
- Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating ResultsPR Newswire(Thu, Aug 8)
- Aeterna Zentaris to Present at Upcoming Canaccord Genuity Global Growth Conference in BostonCNW Group(Wed, Aug 7)
- Aeterna Zentaris to Present at Upcoming Canaccord Genuity Global Growth Conference in BostonPR Newswire(Wed, Aug 7)
- Aeterna Initiates Phase III Study on AEZS-108Zacks(Fri, Aug 2)
- Aeterna Zentaris to Announce Second Quarter 2013 Financial and Operating Results on August 8, 2013PR Newswire(Thu, Aug 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 0.74 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.04 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.14 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Aeterna Zentaris Inc., a specialty biopharmaceutical company, is engaged in developing and commercializing treatments in oncology and endocrinology worldwide.
View More
0.41%